Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

[1]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[2]  P. Kantoff,et al.  The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). , 2015, Journal of the National Cancer Institute.

[3]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. , 2015, The New England journal of medicine.

[4]  I. Tannock,et al.  Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  A. Ravaud,et al.  Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. , 2015, The Lancet. Oncology.

[6]  F. Saad,et al.  Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. , 2015, BoneKEy reports.

[7]  R. Hannan,et al.  A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Carles,et al.  A phase IIb trial of docetaxel concurrent with radiotherapy plus hormotherapy versus radio hormonotherapy in high-risk localized prostate cancer (QRT SOGUG trial): Preliminary report for design, tolerance, and toxicity. , 2015 .

[9]  G. Deplanque,et al.  Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial. , 2015 .

[10]  Kurt Miller,et al.  Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). , 2015, European urology.

[11]  Matthew R. Sydes,et al.  Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  B. Delahunt,et al.  Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial. , 2014, The Lancet. Oncology.

[13]  S. Culine,et al.  Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial. , 2014 .

[14]  M. Gleave,et al.  A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results. , 2014 .

[15]  M. Kattan,et al.  Adjuvant leuprolide with or without docetaxel in patients with high‐risk prostate cancer after radical prostatectomy (TAX‐3501) , 2013, Cancer.

[16]  S. Culine,et al.  Effect of addition of docetaxel (D) to hormonal therapy (HT) versus HT alone on quality of life: Results from a phase III study in non-metastatic high-risk prostate cancer (PC) patients (pts) with a rising PSA status. , 2013 .

[17]  E. Small,et al.  Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (Alliance). , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[19]  C. Mathers,et al.  GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer , 2013 .

[20]  Y. Kondo,et al.  Randomized study on the effect of zoledronic acid treatment for prostate cancer with bone metastasis during initial combined androgen blockade. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[22]  J F Tierney,et al.  A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. , 2011, Journal of clinical epidemiology.

[23]  I. Pedley,et al.  Tolerability and efficacy of anti-androgen manipulation versus taxotere and anti-androgen manipulation in patients with hormone-naive, high-risk/metastatic prostate cancer: A phase II, open-labeled, randomized study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Kellokumpu-Lehtinen,et al.  High toxicity in patients receiving adjuvant docetaxel plus hormone treatment after radical radiotherapy for high-risk prostate cancer: A preplanned safety report of SPCG 13 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[26]  W. Dahut,et al.  An update on androgen deprivation therapy for prostate cancer. , 2010, Endocrine-related cancer.

[27]  C. Yiannoutsos,et al.  A randomized placebo-controlled trial of daily high-dose oral risedronate in men with metastatic prostate cancer commencing androgen deprivation therapy (ADT). , 2010 .

[28]  Thomas E. Moritz,et al.  Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. , 2009, The Journal of urology.

[29]  M. Parmar,et al.  Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials , 2009, The Lancet. Oncology.

[30]  S. Fosså,et al.  Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial , 2009, The Lancet.

[31]  S. Trivedi,et al.  Prevention of Bone Mineral Loss by Zoledronic Acid in Men with Prostate Carcinoma Receiving Androgen Deprivation Therapy: A Prospective Randomized Trial in an Indian Population , 2008, Current Urology.

[32]  J. Glanville,et al.  Searching for Studies , 2008 .

[33]  J. Manríquez,et al.  A highly sensitive search strategy for clinical trials in Literatura Latino Americana e do Caribe em Ciências da Saúde (LILACS) was developed. , 2008, Journal of clinical epidemiology.

[34]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Ryan,et al.  Suppression of bone density loss and bone turnover in patients with hormone‐sensitive prostate cancer and receiving zoledronic acid , 2007, BJU international.

[36]  C. Bennett,et al.  Effects of zoledronate (Z) on bone mineral density (BMD) among African Americans (AA) with advanced prostate cancer, without skeletal metastases, receiving androgen ablation therapy , 2007 .

[37]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[38]  P. Rodrigues,et al.  Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open‐label controlled study , 2007, International journal of urology : official journal of the Japanese Urological Association.

[39]  J. Gottesman,et al.  The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. , 2007, Clinical genitourinary cancer.

[40]  T. Wilt,et al.  Bisphosphonates for advanced prostate cancer. , 2006, The Cochrane database of systematic reviews.

[41]  C. Ryan,et al.  Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. , 2006, The Journal of urology.

[42]  R Brian Haynes,et al.  Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. , 2006, Journal of the Medical Library Association : JMLA.

[43]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[45]  N. Clarke,et al.  Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer. , 2004, European urology.

[46]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[47]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[48]  M. Parmar,et al.  First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence , 2002, British Journal of Cancer.

[49]  F. Saad,et al.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. , 2002, Journal of the National Cancer Institute.

[50]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[51]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[52]  M. Palmer.  Clinical Trials: A Practical Approach , 1985 .